Albatroz Therapeutics, a biotechnology company specializing in developing novel therapies for cancer and other indications, has recently announced its membership with Johnson & Johnson Innovation – JLABS Singapore. The company is focused on revolutionizing cancer treatment by targeting critical pathways involved in tumor growth and metastasis. By joining JLABS Singapore, Albatroz gains access to mentorship,…
McKesson Corporation announced the acquisition of a controlling interest in Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). McKesson will purchase approximately 70% ownership for $2.49 billion in cash. The transaction is subject to customary closing conditions and regulatory clearances. The funding will be used…
Halda Therapeutics, a biotechnology company specializing in RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) therapeutics for cancer treatment, has secured $126 million in a Series B extension funding round. The funding will support the advancement of two RIPTAC candidates into clinical trials for prostate cancer and breast cancer, specifically in the metastatic setting where standard treatments…
Pinetree Therapeutics, Inc., a biotechnology company based in Cambridge, specializing in nextgeneration targeted protein degraders, has successfully completed a Series A funding round, raising $17 million. The funding will support the continued development of the companys multispecific antibody degraders for oncology and other therapeutic areas. Led by STIC Investments and DSC Investment, the funding round…
Radionetics Oncology, a biotechnology company specializing in developing small molecule radiopharmaceuticals targeting G protein coupled receptors (GPCRs) for solid tumor treatment, has formed a strategic relationship with Eli Lilly and Company. The agreement includes an upfront cash payment of $140 million to Radionetics, with an option for Lilly to acquire Radionetics for $1 billion after…
NPower Medicine, a company revolutionizing the clinical trial process in oncology, has announced the initial close of its Series B funding round, raising a total of $72 million. The funding will be utilized to expand the companys network of oncology clinics and collaborations with biopharmaceutical companies, leveraging its unique platform for integrating clinical research into…
NPower Medicine, a company reimagining the clinical trial process, is partnering with Merck to enhance clinical research for oncologists and their patients. The collaboration aims to increase physician participation in clinical trials and provide greater access to research opportunities for eligible patients. NPower Medicines realtime registry and pointofcare platform integrates technology, AI, and research staff…
Envisagenics, an AIdriven biotechnology company focused on RNA splicing therapeutics, announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development, Red Cell Partners, and new strategic investor Bristol Myers Squibb. The funding will be used to further develop Envisagenics pipeline of novel oncology assets using their AI…
Pheon Therapeutics, a leading AntibodyDrug Conjugate (ADC) specialist focused on developing nextgeneration ADCs for hardtotreat cancers, has successfully completed a $120m Series B financing round. The funding will support the development of Pheons pipeline of innovative ADCs, with a particular focus on advancing three firstinclass ADC assets through clinical proof of concept. The funding round…
Asher Biotherapeutics is a biotechnology company focused on developing preciselytargeted immunotherapies for cancer, autoimmune, and infectious diseases. The company announced the closing of a Series C financing round, raising $55 million. The funding will be used to advance the clinical development of their lead program, AB248, a novel CD8 T cell selective IL2 designed to…